Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Med Pediatr Oncol
; 36(1): 194-6, 2001 Jan.
Article
em En
| MEDLINE
| ID: mdl-11464881
ABSTRACT
BACKGROUND:
Gangliosicle GD2 is abundant on human neuroblastoma (NB). Monoclonal antibody 3F8 targeted to GD2 may have imaging and therapeutic potential. Antigen-negative clones can escape immune-mediated attack leading to clinical resistance or recurrence. PROCEDURE Among 95 evaluable patients treated intravenously with 3F8 (94 Stage 4, 1 Stage 3), 66 received nonradiolabeled 3F8, 11 received 131-iodine-labeled-3F8 (8-28 mCi/kg) with autologous bone marrow rescue, and 18 received both forms of treatment. Prior to treatment, 90 patients tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 68), tumor immunohistochemistry (n = 20), or diagnostic radioimmunoscintigraphy (n = 2).RESULTS:
Of 62 patients who had refractory or recurrent neuroblastoma following 3F8 treatment, 61 (98%) tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 51) or tumor immunohistochemistry (n = 10). The sole tumor that lost GD2 expression underwent phenotypic transformation into a pheochromocytoma-like tumor.CONCLUSIONS:
The persistence of GD2 expression in refractory or recurrent NB suggests that complete antigen loss is an uncommon event and cannot account for treatment failure.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoglobulina G
/
Biomarcadores Tumorais
/
Imunização Passiva
/
Radioimunoterapia
/
Imunoconjugados
/
Gangliosídeos
/
Radioisótopos do Iodo
/
Anticorpos Monoclonais
/
Antígenos de Neoplasias
/
Neuroblastoma
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Med Pediatr Oncol
Ano de publicação:
2001
Tipo de documento:
Article
País de afiliação:
Estados Unidos